Biogen: agreement to acquire HI-Bio

(CercleFinance.com) - Biogen announces an agreement to acquire Human Immunology Biosciences (HI-Bio), an unlisted clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs).


The transaction will include felzartamab, a promising potential therapeutic candidate in a range of IMDs, which has demonstrated clinical proof-of-concept in rare indications and is due to enter Phase III development.

Biogen will make an upfront payment of $1.15bn, plus potential milestone payments of up to $650m. Subject to customary conditions and approvals, the transaction is expected to close in Q3 2024.


Copyright (c) 2024 CercleFinance.com. All rights reserved.